Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Ono Pharmaceutical Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Non small cell lung cancer (Squamous or non-squamous)
At least one prior anti-cancer therapy that did not work
ECOG Performance Scale 0-1
You may not be if
Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug
Active, known or suspected autoimmune disease or infection
Prior immuno-oncology therapy
Corticosteroids within 2 weeks of study drug administration
Clareo Health | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
